Syndax Pharmaceuticals reported its first quarter of 2026 financial results with ongoing commercialization of two approved cancer therapies, Revuforj and Niktimvo, underpinned by a key collaboration with Incyte. The company continues to invest heavily in research and development, sharing costs and profits on axatilimab-based therapies in the U.S., while maintaining a strong balance sheet with cash reserves of $130.9 million and a current ratio above 5. Syndax faces typical biotech industry risks such as regulatory uncertainties and clinical trial dependencies but benefits from proprietary licensing agreements that support its product pipeline and competitive positioning.